Progestin intrauterine device in an adolescent with grade 2 endometrial cancer

Alaina J. Brown; Shannon N. Westin; Russell R. Broaddus; Kathleen Schmeler

doi:10.1097/AOG.0b013e318234d97c

Progestin intrauterine device in an adolescent with grade 2 endometrial cancer

Alaina J. Brown, Shannon N. Westin, Russell R. Broaddus, Kathleen Schmeler

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Abstract

BACKGROUND: The treatment of endometrial cancer in young women who desire future fertility poses several challenges. Oral progestin and progestin-releasing intrauterine devices (IUDs) have been shown to result in regression of endometrial hyperplasia and grade 1 endometrioid endometrial carcinoma. However, limited data are available on the use of these methods in women with grade 2 disease. CASE: An 18-year-old nulliparous woman was diagnosed with a grade 2 endometrial adenocarcinoma. She desired future fertility and therefore underwent placement of a levonorgestrel-releasing IUD. The patient subsequently underwent endometrial sampling every 3 months and remained disease-free 13 months after initial IUD placement. CONCLUSION: A progestin-releasing IUD may be a valid treatment option for grade 2 endometrial cancer in young women who desire to retain fertility.

Original language	English (US)
Pages (from-to)	423-426
Number of pages	4
Journal	Obstetrics and gynecology
Volume	119
Issue number	2 PART 2
DOIs	https://doi.org/10.1097/AOG.0b013e318234d97c
State	Published - Feb 2012

ASJC Scopus subject areas

Obstetrics and Gynecology

Access to Document

10.1097/AOG.0b013e318234d97c

Cite this

@article{3a0abfa07f894eb99f094cef29e948e5,

title = "Progestin intrauterine device in an adolescent with grade 2 endometrial cancer",

abstract = "BACKGROUND: The treatment of endometrial cancer in young women who desire future fertility poses several challenges. Oral progestin and progestin-releasing intrauterine devices (IUDs) have been shown to result in regression of endometrial hyperplasia and grade 1 endometrioid endometrial carcinoma. However, limited data are available on the use of these methods in women with grade 2 disease. CASE: An 18-year-old nulliparous woman was diagnosed with a grade 2 endometrial adenocarcinoma. She desired future fertility and therefore underwent placement of a levonorgestrel-releasing IUD. The patient subsequently underwent endometrial sampling every 3 months and remained disease-free 13 months after initial IUD placement. CONCLUSION: A progestin-releasing IUD may be a valid treatment option for grade 2 endometrial cancer in young women who desire to retain fertility.",

author = "Brown, {Alaina J.} and Westin, {Shannon N.} and Broaddus, {Russell R.} and Kathleen Schmeler",

year = "2012",

month = feb,

doi = "10.1097/AOG.0b013e318234d97c",

language = "English (US)",

volume = "119",

pages = "423--426",

journal = "Obstetrics and gynecology",

issn = "0029-7844",

publisher = "Lippincott Williams and Wilkins",

number = "2 PART 2",

}

TY - JOUR

T1 - Progestin intrauterine device in an adolescent with grade 2 endometrial cancer

AU - Brown, Alaina J.

AU - Westin, Shannon N.

AU - Broaddus, Russell R.

AU - Schmeler, Kathleen

PY - 2012/2

Y1 - 2012/2

N2 - BACKGROUND: The treatment of endometrial cancer in young women who desire future fertility poses several challenges. Oral progestin and progestin-releasing intrauterine devices (IUDs) have been shown to result in regression of endometrial hyperplasia and grade 1 endometrioid endometrial carcinoma. However, limited data are available on the use of these methods in women with grade 2 disease. CASE: An 18-year-old nulliparous woman was diagnosed with a grade 2 endometrial adenocarcinoma. She desired future fertility and therefore underwent placement of a levonorgestrel-releasing IUD. The patient subsequently underwent endometrial sampling every 3 months and remained disease-free 13 months after initial IUD placement. CONCLUSION: A progestin-releasing IUD may be a valid treatment option for grade 2 endometrial cancer in young women who desire to retain fertility.

AB - BACKGROUND: The treatment of endometrial cancer in young women who desire future fertility poses several challenges. Oral progestin and progestin-releasing intrauterine devices (IUDs) have been shown to result in regression of endometrial hyperplasia and grade 1 endometrioid endometrial carcinoma. However, limited data are available on the use of these methods in women with grade 2 disease. CASE: An 18-year-old nulliparous woman was diagnosed with a grade 2 endometrial adenocarcinoma. She desired future fertility and therefore underwent placement of a levonorgestrel-releasing IUD. The patient subsequently underwent endometrial sampling every 3 months and remained disease-free 13 months after initial IUD placement. CONCLUSION: A progestin-releasing IUD may be a valid treatment option for grade 2 endometrial cancer in young women who desire to retain fertility.

UR - http://www.scopus.com/inward/record.url?scp=84858784795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858784795&partnerID=8YFLogxK

U2 - 10.1097/AOG.0b013e318234d97c

DO - 10.1097/AOG.0b013e318234d97c

M3 - Article

C2 - 22270425

AN - SCOPUS:84858784795

SN - 0029-7844

VL - 119

SP - 423

EP - 426

JO - Obstetrics and gynecology

JF - Obstetrics and gynecology

IS - 2 PART 2

ER -

Progestin intrauterine device in an adolescent with grade 2 endometrial cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this